Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 3/20 | 0.38 |
| ▸ | FABP4 | P15090 | 1/20 | 0.36 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.33 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27862253 | 0.89 | FABP4 (0.38) | HTR6FABP4PLA2G4AEGLN1TBXA2R | |
| SCHEMBL8577106 | 0.86 | HTR6 (0.37) | HTR6FABP4HDAC6HDAC8HDAC1 | |
| SCHEMBL6993132 | 0.85 | FABP4 (0.35) | HTR6FABP4PLA2G4AEGLN1TBXA2R | |
| SCHEMBL818662 | 0.85 | PLA2G2A (0.42) | HTR6FABP4EGLN1 | |
| SCHEMBL6978340 | 0.79 | PLA2G2A (0.41) | HTR6TBXA2R | |
| SCHEMBL8577109 | 0.78 | HTR6 (0.36) | HTR6 | |
| SCHEMBL6983124 | 0.78 | PLA2G2A (0.40) | HTR6FABP4 | |
| SCHEMBL6978338 | 0.77 | HTR6 (0.36) | HTR6FABP4HDAC6HDAC8HDAC2 | |
| SCHEMBL6129626 | 0.76 | HTR6 (0.37) | HTR6FABP4 | |
| SCHEMBL8575155 | 0.74 | HTR6 (0.33) | HTR6FABP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2003525901-A | — | — | 2003-09-02 | — | — | JP | claimed |
| EP-1265607-A2 | METHOD FOR THE TREATMENT OF RENAL DYSFUNCTION WITH sPLA 2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-12-18 | — | — | EP | claimed |
| WO-2001066110-A2 | METHOD FOR THE TREATMENT OF RENAL DYSFUNCTION WITH sPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-09-13 | — | — | WO | claimed |
| WO-2001055108-A2 | USE OF SPL A2 INHIBITORS FOR THE TREATMENT OF INFLAMMATION | ELI LILLY AND COMPANY (US) | 2001-08-02 | — | — | WO | claimed |
| WO-1998018464-A1 | SUBSTITUTED TRICYCLICS | ELI LILLY AND COMPANY (US) | 1998-05-07 | — | — | WO | claimed |
| WO-1998018464-A1 | SUBSTITUTED TRICYCLICS | ELI LILLY AND COMPANY (US) | 1998-05-07 | — | — | WO | disclosed |